西罗莫司怎么服用？

It is a macrolide antibiotic that can be used long-term to help improve disease. Sirolimus blocks signal transduction through different cytokine receptors and blocks the process of T lymphocytes and other cells from the G1 phase to the S phase, thereby exerting an immunosuppressive effect. So, how to take Sirolimus from Biocon India?

Sirolimus should only be used by physicians experienced with immunosuppressive therapy and managing kidney transplant patients. Patients should not take medication blindly. Sirolimus needs to be started as soon as possible after transplantation.

The recommended loading dose of rapamycin for renal transplant patients is 6 mg and the maintenance dose is 2 mg/day. Tablets need to be swallowed whole and not chewed or broken. If the patient has difficulty swallowing, an oral solution should be chosen. Sirolimus can be taken with or without food. If the dose needs to be adjusted, it should be done under the advice of a doctor.

Sirolimus, a macrolide compound, is a potentially new and potent immunosuppressant with less toxicity discovered so far, providing a new treatment alternative for transplant recipients. Patients need to follow the doctor's instructions carefully and use the medicine in the correct way during the treatment process. If there are special circumstances, please inform the doctor in time.

Biocon is one of India's three largest biotech companies and an emerging global biopharmaceutical company that is committed to reducing the cost of treatment for chronic diseases such as diabetes, cancer and autoimmune disease patients by leveraging India's cost advantages and partners to provide affordable healthcare solutions to healthcare systems around the world.

Sirolimus inhibits the activation and proliferation of T lymphocytes stimulated by antigens and cytokines (interleukins IL-2, IL-4 and IL-15). It also inhibits the production of antibodies. In cells, it binds to the immunophilin, FK-binding protein-12 (FKBP-12), to generate the FKBP-12 immunosuppressive complex. This complex binds to the mammalian sirolimus BA molecule (mTOR, a key regulatory kinase) and inhibits its activity, thereby inhibiting the progression from the G1 phase to the S phase in the cell cycle.